<DOC>
	<DOCNO>NCT00797303</DOCNO>
	<brief_summary>Eight patient corneal neovascularization treat subconjunctival injection 1.25 mg bevacizumab follow-up least 2 month . All patient persistent corneal neovascularization least 6 month unresponsive treatment . Patients monitor ophthalmic exam anterior segment photography .</brief_summary>
	<brief_title>The Effect Bevacizumab Corneal Neovascularization</brief_title>
	<detailed_description>To evaluate effect repeat subconjunctival bevacizumab ( AvastinÂ® , Roche , Rio de Janeiro , Brazil ) inflammatory corneal neovascularization . Eight patient corneal neovascularization treat subconjunctival injection 1.25 mg bevacizumab follow-up least 2 month . All patient persistent corneal neovascularization least 6 month unresponsive treatment . Patients monitor ophthalmic exam anterior segment photography .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Corneal Neovascularization Stable lesion Diabetes Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>cornea</keyword>
	<keyword>neovascularization</keyword>
</DOC>